Deepwise Medical Unveils New AI-Powered Platforms at 2026 China Medical Equipment Exhibition, Marking Strategic Shift Toward End-to-End Healthcare Ecosystem Empowerment

Recently, the China Medical Equipment Conference and the 2026 Medical Equipment Exhibition grandly opened in Chongqing. DeepWise showcased its core products, including the Deepwise MetAI X multimodal intelligent imaging large model capability platform and smart equipment. At the exhibition, DeepWise made a significant announcement by launching two new products: the Prostate MRI AI-Assisted Diagnosis System and the Chest X-Ray Large Model Report Center. These innovations precisely address the needs of specific clinical scenarios, further enriching DeepWise’s multimodal AI product portfolio. This marks a strategic leap from “single-point efficiency improvement” to “full-process system empowerment,” comprehensively demonstrating the company’s robust innovative capabilities and full-process strategic layout in the field of medical AI.

The China Medical Equipment Conference and 2026 Medical Equipment Exhibition, hosted by the China Association of Medical Equipment, was grandly held in Chongqing. The exhibition showcased over ten thousand new products, technologies, applications, and methods in the field of medical equipment, comprehensively presenting the latest advancements in the industry.

Academician Cai Xiujun of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, presented innovations and practices in surgical procedures in his keynote address at the conference. He stated that medical robots, particularly those manufactured in China, have achieved a high level of maturity in remote minimally invasive surgical technologies. AI-driven enterprises represented by DeepWise have played a significant supporting and leading role in areas such as precision diagnosis and treatment across the full disease continuum, the construction of multi-agent collaborative decision-making systems, and validation through real-world studies.

DeepWise made a striking appearance with its Deepwise MetAI X intelligent imaging large model capability platform, a full series of smart equipment, and multiple AI solutions for intelligent research. It also unveiled two new products: the Prostate MR AI-Assisted Diagnosis System and the Chest X-Ray Large Model Report Center. This product launch marks DeepWise’s thorough breakthrough from the limitations of single-stage empowerment, reshaping imaging diagnosis and specialty care models through systematic thinking. It signifies a strategic leap in AI technology from improving efficiency at individual points and empowering local tools to enabling end-to-end processes and reconstructing the diagnostic and treatment ecosystem.

In his address at an academic conference, Qiao Xin, Co-founder and CEO of DeepWise, stated that the integration of medical imaging and AI has entered a critical phase. Key challenges—including optimization of multimodal large models, real-world clinical validation, and data security and compliance—require collaborative efforts among academia, industry, research institutions, and healthcare providers. DeepWise is committed to working closely with peers to accelerate the translation of research into practical applications and support the high-quality development of the radiology imaging industry.

DeepWise’s Multimodal Intelligent Imaging Integrated Platform (AI-PACS) is a future-oriented, hospital-wide intelligent imaging information system. Its digitally and intelligently enabled healthcare infrastructure serves as the core vehicle for transitioning from AI empowerment of standalone products to the systemic reconstruction of value. Innovatively adopting a hyper-converged architecture, the platform deeply embeds AI capabilities within the PACS system, eliminating the fragmented experience associated with traditional plug-in AI solutions. Through comprehensive end-to-end integration, Deepwise MetAI X consolidates multimodal data across radiology, ultrasound, endoscopy, nuclear medicine, and pathology, achieving an integrated workflow for clinical image interpretation, intelligent analysis, structured reporting, and research data management. This significantly enhances the efficiency of image retrieval and processing. Simultaneously, it establishes a unified, efficient, and scalable hospital-wide imaging data asset center, enabling localized high-efficiency interaction and linear scalability between AI and business systems. By realizing the intelligent fusion and orchestration of clinical and research data, the platform fundamentally resolves bottlenecks in massive data management, empowers clinical workflows with AI, and drives the comprehensive transformation of hospital imaging departments from cost centers to value centers.

The platform has been deployed and applied in multiple provinces and municipalities, including Henan, Xinjiang, Shaanxi, and Jiangsu. By leveraging a revolutionary “dual-bus” architecture for medical imaging and deconstructed data, it establishes a hospital-wide intelligent imaging hub, enabling integrated coordination across “medical imaging–lesion information–report quality control–intelligent generation–data management.” In his academic presentation, Professor Wu Xiaoping from Xi’an Central Hospital pointed out that AI-PACS allows physicians to focus solely on key decision-making, significantly enhancing diagnostic efficiency and accuracy.

DeepWise’s flagship smart equipment—the Canglan Linglong Intelligent Bone Densitometer and the Intelligent Low-Dose X-Ray Bone Age Assessment System—drew significant attention from professionals at the exhibition booth. These two intelligent devices offer advantages such as compact and reliable design, intelligent precision, full shielding protection, and convenient wireless operation. They are widely applicable across the entire care continuum, including disease screening, auxiliary diagnosis, treatment efficacy monitoring, and prognostic follow-up. By providing intelligent and precise assessment results, they effectively assist physicians in comprehensively tracking disease progression and scientifically guiding clinical interventions and regular follow-ups. This truly shifts the focus of disease diagnosis to an earlier stage, delivering more comprehensive proactive health services to the public and establishing a more convenient, precise, and intelligent new model of health management for the national prevention and control of major chronic diseases.

On the opening day, DeepWise held a new product launch ceremony at its booth, drawing significant attention and acclaim from the industry. At the event, several leaders from the China Association of Medical Equipment attended, joining industry luminaries and scholars to witness this remarkable moment.

Prostate diseases, particularly prostate cancer, are highly prevalent conditions affecting the male urogenital system and have become a significant malignant threat to men's health. Early screening and precise diagnosis are key to improving prognosis and survival rates. In clinical practice, the occult location of prostate lesions, the propensity for missing diagnoses in the transitional zone, and the difficulty in differentiating between benign and malignant conditions pose major challenges. Traditional imaging diagnosis relies heavily on physicians' experience, resulting in low detection rates for small lesions and potential deviations in staging assessment, which constitute core pain points in clinical diagnosis and treatment. Prostate magnetic resonance (MR) imaging, leveraging its multi-parametric imaging capabilities and high soft-tissue resolution, serves as the cornerstone imaging modality for the precise diagnosis and staging of prostate diseases, playing a critical role in the identification of early-stage lesions and the assessment of tumor aggressiveness.

DeepWise’s newly launched AI-assisted diagnostic system for prostate MR imaging precisely addresses key challenges in the diagnosis and treatment of prostate diseases. Leveraging multimodal image processing technology and proprietary core algorithms, the system supports intelligent recognition of multi-sequence images, automatic segmentation and zonal mapping of the prostate gland, as well as automated lesion detection and PI-RADS scoring. It features one-click generation of structured reports, thereby integrating the entire workflow of prostate disease screening, diagnosis, staging, and follow-up. By accurately and rapidly identifying minute lesions, the system combines image interpretation, intelligent analysis, lesion localization, and report generation into a unified platform. This significantly enhances diagnostic efficiency and consistency, providing clinicians with reliable decision support while facilitating standardized management of research data. Ultimately, it promotes a transition toward precision and standardization in prostate disease diagnosis and treatment, establishing a comprehensive support framework for the entire precision care pathway.

With the official integration of the AI-assisted diagnostic system for prostate MRI, DeepWise has established a comprehensive and well-rounded portfolio of MRI AI products, delivering precise AI-assisted diagnostics for diseases affecting multiple anatomical regions and physiological systems. The product suite currently covers core clinical scenarios including brain MRI, cardiac MRI, breast MRI, and knee joint MRI, comprehensively empowering imaging diagnosis and clinical treatment.

Chest digital radiography (DR), as the most widely used imaging modality in healthcare institutions, covers a full range of scenarios including common disease screening, health check-ups, and initial emergency diagnosis, serving as the core equipment for primary-care imaging. However, inconsistent interpretation standards frequently lead to discrepant reports, and the low level of standardization and homogenization directly constrains the quality of primary healthcare services. Leveraging general-purpose large language models with specialized training for medical scenarios to address report standardization challenges and strengthen diagnostic capabilities at the primary care level has become a key pathway for advancing smart healthcare into grassroots settings.

DeepWise Chest X-ray Large Model Reporting Center deeply integrates medical large models with imaging scenarios. Trained using a “clinician’s mindset,” it addresses chest X-ray diagnostic needs for dozens of diseases, enabling end-to-end intelligent workflows that include critical value management and automated generation of structured reports. It truly achieves comprehensive coverage of all X-ray examination scenarios, fundamentally meeting the essential clinical demands for screening and diagnosing thoracic diseases. As chest X-ray is the preferred modality for primary care imaging diagnosis, the launch of the DeepWise Chest X-ray Large Model Reporting Center helps primary healthcare institutions significantly improve interpretation efficiency and diagnostic accuracy, facilitating the decentralization of high-quality medical resources and ensuring equitable access to standardized medical services for broader populations at the grassroots level.

DeepWise’s debut at the 2026 Medical Equipment Exhibition serves as a key platform to showcase its technological innovations and integrated hardware-software capabilities, marking a significant milestone in its strategic transition from “point-based enablement” to “system-wide enablement.” Moving forward, DeepWise will remain committed to its development philosophy of “clinical value as the core and technological innovation as the driver.” Leveraging its multimodal large-model foundation, the company will continue to refine more innovative and systematic AI healthcare solutions, accelerating the evolution of medical AI from isolated tools to a comprehensive ecosystem overhaul. This will ensure that intelligent technologies are seamlessly integrated into the entire spectrum of daily clinical practice and scientific research across healthcare institutions at all levels. By continuously pushing technological boundaries, DeepWise will deliver more advanced and practical AI products and services to enhance primary healthcare capabilities, optimize hospital operational efficiency, and safeguard public health, thereby contributing robustly to the high-quality development of China’s medical equipment industry and jointly building a brighter future for healthcare.